An internationally-recognized leader in pharmacogenomics and genomic medicine, with over 300 peer-reviewed publications and over $50M in research funding as principal investigator. In 2015, 2016, 2017, and 2018 she was named a Clarivate Analytics Highly Cited Researcher, indicating the top 1% of most highly cited scientists globally in the previous decade. Had numerous service roles, including the NIH, FDA, CDC, American Heart Association, American College of Clinical Pharmacy (ACCP), and ASCPT. Served as President in 2016-17. Dr. Johnson received numerous awards: Elected to the National Academy of Medicine, inducted as a Fellow of the American Association for the Advancement of Science and fellowship in three other societies, recipient of Leon I Goldberg Young Investigator Award (ASCPT), Volwiler Research Achievement Award from American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award, Paul Parker Medal (ACCP), the ASCPT Rawls Palmer Progress in Medicine Award, the PMWC Luminary Award, among others.
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.